FMP
Advaxis, Inc.
ADXS
PNK
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
0.03 USD
0 (0%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
2.33M
253k
3.24M
250k
13k
7.27k
4.07k
2.28k
1.27k
712.06
Revenue %
-
-89.16
1.18k
-92.28
-94.8
-44.06
-44.06
-44.06
-44.06
Ebitda
-17.56M
-24.39M
-18.77M
-15.78M
-35.87M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Ebitda %
-752.4
-9.64k
-579.2
-6.31k
-275.92k
-100
-100
-100
-100
Ebit
-19.04M
-26.37M
-19.76M
-16.09M
-36.24M
-7.27k
-4.07k
-2.28k
-1.27k
-712.06
Ebit %
-815.94
-10.42k
-609.75
-6.44k
-278.75k
-100
-100
-100
-100
Depreciation
1.48M
1.98M
990k
314k
369k
5.73k
3.21k
1.79k
1k
561.24
Depreciation %
63.54
781.82
30.56
125.6
2.84k
78.82
78.82
78.82
78.82
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
